Profil
Zina Affas Besse currently holds the position of Director at Eyenuk, Inc. since 2022.
Also holds the role of Director at Alydia Health, Inc. The role of Director at LimmaTech Biologics AG has been held since 2023.
Serves as Partner at AXA IM Alts since 2022.
Acts as Advisor at LHGP Asset Management LLP (Private Equity).
Education includes undergraduate and doctorate degrees from the University of Nottingham Malaysia.
Postes actifs de Zina Affas Besse
| Sociétés | Poste | Début |
|---|---|---|
Alydia Health, Inc.
Alydia Health, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes medical devices | Directeur/Membre du Conseil | - |
Eyenuk, Inc.
Eyenuk, Inc. Medical SpecialtiesHealth Technology Develops and manufactures diabetic retinopathy diagnostic devices | Directeur/Membre du Conseil | 17/10/2022 |
LHGP Asset Management LLP (Private Equity)
LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management seeks investment opportunities located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for late stage capital requirements with an average investment size of USD 10 million. | Consultant / Advisor | - |
LimmaTech Biologics AG
LimmaTech Biologics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops vaccines for prevention of life-threatening diseases | Directeur/Membre du Conseil | 09/10/2023 |
Formation de Zina Affas Besse
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
LHGP Asset Management LLP (Private Equity)
LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management seeks investment opportunities located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for late stage capital requirements with an average investment size of USD 10 million. | Finance |
Eyenuk, Inc.
Eyenuk, Inc. Medical SpecialtiesHealth Technology Develops and manufactures diabetic retinopathy diagnostic devices | Health Technology |
Alydia Health, Inc.
Alydia Health, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes medical devices | Health Technology |
LimmaTech Biologics AG
LimmaTech Biologics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops vaccines for prevention of life-threatening diseases | Health Technology |
University of Nottingham Malaysia
University of Nottingham Malaysia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















